07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

DC Bead regulatory update

BTG and partner SciClone Pharmaceuticals Inc. (NASDAQ:SCLN, Foster City, Calif.) said the China Food and Drug Administration (CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors, such as hepatocellular carcinoma (HCC). DC...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

BTG, Eisai sales and marketing update

Eisai launched DC Bead in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). Additionally, Eisai said the device was classified in the special treatment materials (STM) category...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

BTG, Eckert & Ziegler deal

Eckert & Ziegler acquired all of BTG's brachytherapy assets, including products which are used to treat early stage prostate cancer, associated IP and a facility in Oxford, Conn. BTG will receive $5 million up front...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

DC Bead regulatory update

Eisai disclosed in its 1Q13 earnings that DC Bead was approved in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). DC Bead is approved in the U.S....
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

DC Bead: Phase III started

Eisai disclosed in its 1Q12 earnings that it began an open-label, Japanese Phase III trial to evaluate DC Bead in patients with hypervascularized tumors or arteriovenous malformation. Eisai has rights to DC Bead from Biocompatibles...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

BTG, AstraZeneca deal

AstraZeneca declined to exercise an option to license Type II diabetes candidate CM-3 from BTG. According to BTG, AstraZeneca made the decision after reviewing undisclosed Phase I data for the glucagon-like peptide-1 (GLP-1) analog. AstraZeneca...
23:28 , May 13, 2011 |  BC Extra  |  Company News

AstraZeneca declines BTG option

AstraZeneca plc (LSE:AZN; NYSE:AZN) declined to exercise an option to license Type II diabetes candidate CM-3 from BTG plc (LSE:BGC). According to BTG, AstraZeneca made the decision after reviewing undisclosed Phase I data for the...
08:00 , Feb 7, 2011 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 2/4 cls Amicus Therapeutics Inc. (NASDAQ:FOLD) Leerink Joseph Schwartz Upgrade Market outperform (from market perform) 13% $6.14 Schwartz raised his target to $8 from...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

LC Bead regulatory update

Eisai submitted a marketing application to the Japanese Ministry of Health and Welfare for Embolic Bead E7040 to treat hepatocellular carcinoma (HCC) via transcatheter arterial embolization. The drug-eluting bead for controlled release of doxorubicin and...